Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis

Qin Min, Yang Guobing, Yan Jun, Wang Liying, Feng Yu, Wang Dong, Wang Qian, Hou Yanyan, Zhao Jiangshan, Lei Jiaxi, Wang Zhiyi, Jiang Mingzhe, Yu Chenghang, Gavotte Laurent, Frutos Roger. 2024. Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis. Infectious Diseases of Poverty, 13:98, 11 p.

Résumé : Background: Echinococcosis is an infectious parasitic disease that is extremely harmful to human health. Albendazole is provided free of charge to patients requiring medication under the central government finance transfer payment scheme for echinococcosis control and prevention in China. Our aim is to monitor the state of patient medication and its therapeutic impact, which will help improve medication compliance and the therapeutic effect. Methods: Random cluster sampling was used to select 10 echinococcosis-endemic counties in China, and all albendazole-treated patients in these counties were investigated. The chi-square and Kruskal–Wallis tests were used to compare two or more rates or constituent ratios, and multiple logistic regression analysis was used to identify the influencing factors. The records of patients were reviewed to obtain the initial diagnosis results as well as the most recent follow-up results and time, and efficacy was assessed. Results: We examined 899 patient files treated with albendazole in 10 endemic counties. Of the 582 evaluable files, 7.9% did not take albendazole, and 69.2% did not take albendazole regularly. Only 22.9% took albendazole regularly. Of the 536 patients who took albendazole, 242 exhibited adverse reactions. Patients who were Tibetan, herdsmen, received no formal education, used emulsion, and exhibited adverse reactions demonstrated poor compliance. A total of 174 patients with cystic echinococcosis received their most recent imaging follow-up results within one year of the investigation date. Among them, 9 patients met the criteria for cure, accounting for 5.2%; 56 patients showed effectiveness, accounting for 32.2%; 105 patients were deemed ineffective, accounting for 59.8%; 5 patients experienced recurrence, accounting for 2.9%. Conclusions: Albendazole medication compliance in patients with echinococcosis is not ideal. We must prioritize health education and promotion for Tibetans, herdsmen, and those without formal education. Patients who adhered to their medication regimen achieved higher rates of cure and effectiveness. To improve medication compliance and efficacy, it is particularly important to improve communication and medication guidance for patients receiving emulsions and those with adverse reactions after taking albendazole. Simultaneously strengthen patients' attention to follow-up and re-examination.

Mots-clés Agrovoc : echinococcose, albendazole, maladie de l'homme, maladie infectieuse, santé publique, contrôle de maladies, efficacité des médicaments, pharmacologie

Mots-clés géographiques Agrovoc : Chine

Mots-clés libres : Echinococcosis, Tibet Autonomous Region, Pharmacology, Albendazole, Therapy, Medication compliance, Therapeutic effect

Classification Agris : S50 - Santé humaine

Champ stratégique Cirad : CTS 4 (2019-) - Santé des plantes, des animaux et des écosystèmes

Agences de financement hors UE : Gansu Provincial Health Industry Research Plan Project, Natural Science Foundation of Gansu Province

Auteurs et affiliations

• Qin Min, Chinese Center for Disease Control and Prevention (CHN)
• Yang Guobing, Gansu Provincial Center for Disease Control and Prevention (CHN) - auteur correspondant
• Yan Jun, Chinese Center for Disease Control and Prevention (CHN) - auteur correspondant
• Wang Liying, Chinese Center for Disease Control and Prevention (CHN)
• Feng Yu, Gansu Provincial Center for Disease Control and Prevention (CHN)
• Wang Dong, Gansu Provincial Center for Disease Control and Prevention (CHN)
• Wang Qian, Sichuan Provincial Center for Disease Control and Prevention (CHN)
• Hou Yanyan, Chinese Center for Disease Control and Prevention (CHN)
• Zhao Jiangshan, Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention (CHN)
• Lei Jiaxi, Chinese Center for Disease Control and Prevention (CHN)
• Wang Zhiyi, Chinese Center for Disease Control and Prevention (CHN)
• Jiang Mingzhe, Chinese Center for Disease Control and Prevention (CHN)
• Yu Chenghang, Chinese Center for Disease Control and Prevention (CHN)
• Gavotte Laurent, Université de Montpellier (FRA)
• Frutos Roger, CIRAD-BIOS-UMR INTERTRYP (FRA)

Source : Cirad-Agritrop (https://agritrop.cirad.fr/612138/)

Métriques

[ Page générée et mise en cache le 2025-03-02 ]